Dental Health in Asthmatic Children: A South Italy Study

Source: Journal of Dentistry for Children - Category: Dentistry Authors: Tags: Public Health Source Type: research

Related Links:

This study examines the effects of the reform on adverse events, defined as deaths or readmissions occurring within 60 days of hospitalization.Methods: We use Norwegian register data for patients (age 18+) hospitalized between 2009 and 2014 for COPD/asthma (N=25,936), heart failure (N=27,708), hip fracture (N=44,981) and stroke (N=43,313). Our logit models test for conditional effects of the reform, whereby associations between the reform and adverse events vary by whether or not patients were classified as ready for discharge and in need of follow-up care in the community. The models include fixed effects for districts an...
Source: International Journal of Integrated Care - Category: Nursing Source Type: research
AireSone Junior is a wearable respiratory monitor for children that has been developed by AEvice Health, a spinout of Nanyang Technological University in Singapore. The device is attached to a child’s chest at night and listens to their breathi...
Source: Medgadget - Category: Medical Devices Authors: Tags: Exclusive Pediatrics Source Type: blogs
The FDA approved dupilumab as'add-on maintenance therapy in patients with moderate-to-severe asthma aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma. 'FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Pulmonary Medicine News Alert Source Type: news
Regeneron Pharmaceuticals was awarded federal approval Friday to market its Dupixent drug to treat patients with moderate to severe asthma. The drug developer, which makes bulk medications at its East Greenbush, New York, manufacturing complex, already had been marketing the medication for use in patients with eczema or atopic dermatitis. The U.S. Food and Drug Administration approved Dupixent for eczema patients in March 2017. Then, late last week, the FDA gave Regeneron (Nasdaq: REGN) and its…
Source: Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Vapotherm last week registered for an initial public offering worth nearly $58 million for the respiratory device it’s developing. Exeter, N.H.-based Vapotherm developed the Precision Flow line of devices to provide high-velocity heated, humidified and oxygenated air to treat patients with conditions such as pneumonia, chronic obstructive pulmonary disease, asthma and heart failure. Some 1,200 of the devices have been sold in the U.S., mostly into hospital ICUs, the company said. In an Oct. 19 filing with the U.S. Securities &Exchange Commission, Vapotherm said the proceeds from the $57.5 million offering ar...
Source: Mass Device - Category: Medical Devices Authors: Tags: Featured Funding Roundup Respiratory Wall Street Beat Vapotherm Source Type: news
Only biologic approved for both moderate and severe asthma patients with eosinophilic phenotype Only biologic approved for oral corticosteroid-dependent asthma, regardless of phenotype Only asthma biologic that offers patient self-administration at h... Biopharmaceuticals, FDA Regeneron Pharmaceuticals, Sanofi, Dupixent, dupilumab, asthma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
Busse WW, Bateman ED, Caplan AL, Kelly HW, O'Byrne PM, Rabe KF, et  al. Combined Analysis of Asthma Safety Trials of Long-Acting β2-Agonists. N Engl J Med 2018;378:2497-505.
Source: The Journal of Pediatrics - Category: Pediatrics Authors: Tags: Current Best Evidence Source Type: research
Source: Revista Paulista de Pediatria - Category: Pediatrics Source Type: research
Conclusions: There was a positive association between homozygous CDX2 polymorphism, asthma and lower FEV1% val ues. CDX2 is capable of modifying cell interaction between VDR and VD, and it could be associated with the prevalence of asthma, and the difficulty in controlling the disease.
Source: Revista Paulista de Pediatria - Category: Pediatrics Source Type: research
Conclusions: The findings demonstrate no differences in cardiorespiratory frequency, O2 saturation, and asthma scores upon administration of β -2 agonist by both inhalation techniques (nebulization and MDI-spacer) to asthmatic patients assisted at pediatric emergency units.
Source: Revista Paulista de Pediatria - Category: Pediatrics Source Type: research
More News: Asthma | Children | Dentistry | International Medicine & Public Health | Study